APO Research
Talk to an analyst

APO RESEARCH · REPORT

TIGIT Therapies

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global TIGIT Therapies Market Analysis and Forecast 2026-2032

30 December 2025195 pages

Choose your research edition.

Industry ResearchTIGIT Therapies Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal TIGIT Therapies Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal TIGIT Therapies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal TIGIT Therapies Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal TIGIT Therapies Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global TIGIT Therapies market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for TIGIT Therapies is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for TIGIT Therapies is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for TIGIT Therapies is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for TIGIT Therapies is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of TIGIT Therapies include Arcus, Astellas, BMS, Compugen, Mereo BioPharma, Seattle Genetics, AstraZeneca, BeiGene and Hengrui Medicine, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for TIGIT Therapies, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of TIGIT Therapies, also provides the revenue of main regions and countries. Of the upcoming market potential for TIGIT Therapies, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the TIGIT Therapies revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global TIGIT Therapies market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for TIGIT Therapies revenue, projected growth trends, production technology, application and end-user industry.

TIGIT Therapies Segment by Company

Arcus

Astellas

BMS

Compugen

Mereo BioPharma

Seattle Genetics

AstraZeneca

BeiGene

Hengrui Medicine

Junshi Biosciences

Roche

Merck

Innovent Biologics

TIGIT Therapies Segment by Type

Monotherapy

Combination Therapy

TIGIT Therapies Segment by Application

Cell Carcinoma

Solid Tumor

TIGIT Therapies Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global TIGIT Therapies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of TIGIT Therapies and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of TIGIT Therapies.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of TIGIT Therapies in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of TIGIT Therapies company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, TIGIT Therapies revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global TIGIT Therapies Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Monotherapy Major Player Table 3. Combination Therapy Major Player Table 4. Global TIGIT Therapies Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Cell Carcinoma Major Player Table 6. Solid Tumor Major Player Table 7. TIGIT Therapies Industry Trends Table 8. TIGIT Therapies Industry Drivers Table 9. TIGIT Therapies Industry Opportunities and Challenges Table 10. TIGIT Therapies Industry Restraints Table 11. Global TIGIT Therapies Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 12. Global TIGIT Therapies Market Size by Region (2021-2026) & (US$ Million) Table 13. Global TIGIT Therapies Market Share by Region (2021-2026) Table 14. Global TIGIT Therapies Market Size by Region (2027-2032) & (US$ Million) Table 15. Global TIGIT Therapies Market Share by Region (2027-2032) Table 16. Global TIGIT Therapies Revenue by Players (US$ Million) & (2021-2026) Table 17. Global TIGIT Therapies Revenue Market Share by Players (2021-2026) Table 18. Global TIGIT Therapies Key Players Ranking, 2024 VS 2025 VS 2026 Table 19. Global TIGIT Therapies Key Players Headquarters & Area Served Table 20. Global TIGIT Therapies Players, Product Type & Application Table 21. Global TIGIT Therapies Players Establishment Date Table 22. Global Players Market Concentration Ratio (CR5 and HHI) Table 23. Global TIGIT Therapies by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 24. Global TIGIT Therapies Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global TIGIT Therapies Revenue by Type (2021-2026) & (US$ Million) Table 26. Global TIGIT Therapies Revenue by Type (2027-2032) & (US$ Million) Table 27. Global TIGIT Therapies Revenue Market Share by Type (2021-2026) Table 28. Global TIGIT Therapies Revenue Market Share by Type (2027-2032) Table 29. Global TIGIT Therapies Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global TIGIT Therapies Revenue by Application (2021-2026) & (US$ Million) Table 31. Global TIGIT Therapies Revenue by Application (2027-2032) & (US$ Million) Table 32. Global TIGIT Therapies Revenue Market Share by Application (2021-2026) Table 33. Global TIGIT Therapies Revenue Market Share by Application (2027-2032) Table 34. Arcus Company Information Table 35. Arcus Business Overview Table 36. Arcus TIGIT Therapies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 37. Arcus TIGIT Therapies Product Portfolio Table 38. Arcus Recent Development Table 39. Astellas Company Information Table 40. Astellas Business Overview Table 41. Astellas TIGIT Therapies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Astellas TIGIT Therapies Product Portfolio Table 43. Astellas Recent Development Table 44. BMS Company Information Table 45. BMS Business Overview Table 46. BMS TIGIT Therapies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. BMS TIGIT Therapies Product Portfolio Table 48. BMS Recent Development Table 49. Compugen Company Information Table 50. Compugen Business Overview Table 51. Compugen TIGIT Therapies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Compugen TIGIT Therapies Product Portfolio Table 53. Compugen Recent Development Table 54. Mereo BioPharma Company Information Table 55. Mereo BioPharma Business Overview Table 56. Mereo BioPharma TIGIT Therapies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Mereo BioPharma TIGIT Therapies Product Portfolio Table 58. Mereo BioPharma Recent Development Table 59. Seattle Genetics Company Information Table 60. Seattle Genetics Business Overview Table 61. Seattle Genetics TIGIT Therapies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Seattle Genetics TIGIT Therapies Product Portfolio Table 63. Seattle Genetics Recent Development Table 64. AstraZeneca Company Information Table 65. AstraZeneca Business Overview Table 66. AstraZeneca TIGIT Therapies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. AstraZeneca TIGIT Therapies Product Portfolio Table 68. AstraZeneca Recent Development Table 69. BeiGene Company Information Table 70. BeiGene Business Overview Table 71. BeiGene TIGIT Therapies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. BeiGene TIGIT Therapies Product Portfolio Table 73. BeiGene Recent Development Table 74. Hengrui Medicine Company Information Table 75. Hengrui Medicine Business Overview Table 76. Hengrui Medicine TIGIT Therapies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Hengrui Medicine TIGIT Therapies Product Portfolio Table 78. Hengrui Medicine Recent Development Table 79. Junshi Biosciences Company Information Table 80. Junshi Biosciences Business Overview Table 81. Junshi Biosciences TIGIT Therapies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. Junshi Biosciences TIGIT Therapies Product Portfolio Table 83. Junshi Biosciences Recent Development Table 84. Roche Company Information Table 85. Roche Business Overview Table 86. Roche TIGIT Therapies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Roche TIGIT Therapies Product Portfolio Table 88. Roche Recent Development Table 89. Merck Company Information Table 90. Merck Business Overview Table 91. Merck TIGIT Therapies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Merck TIGIT Therapies Product Portfolio Table 93. Merck Recent Development Table 94. Innovent Biologics Company Information Table 95. Innovent Biologics Business Overview Table 96. Innovent Biologics TIGIT Therapies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Innovent Biologics TIGIT Therapies Product Portfolio Table 98. Innovent Biologics Recent Development Table 99. North America TIGIT Therapies Revenue by Type (2021-2026) & (US$ Million) Table 100. North America TIGIT Therapies Revenue by Type (2027-2032) & (US$ Million) Table 101. North America TIGIT Therapies Revenue by Application (2021-2026) & (US$ Million) Table 102. North America TIGIT Therapies Revenue by Application (2027-2032) & (US$ Million) Table 103. North America TIGIT Therapies Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 104. North America TIGIT Therapies Revenue by Country (2021-2026) & (US$ Million) Table 105. North America TIGIT Therapies Revenue by Country (US$ Million) & (2027-2032) Table 106. Europe TIGIT Therapies Revenue by Type (2021-2026) & (US$ Million) Table 107. Europe TIGIT Therapies Revenue by Type (2027-2032) & (US$ Million) Table 108. Europe TIGIT Therapies Revenue by Application (2021-2026) & (US$ Million) Table 109. Europe TIGIT Therapies Revenue by Application (2027-2032) & (US$ Million) Table 110. Europe TIGIT Therapies Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 111. Europe TIGIT Therapies Revenue by Country (2021-2026) & (US$ Million) Table 112. Europe TIGIT Therapies Revenue by Country (US$ Million) & (2027-2032) Table 113. China TIGIT Therapies Revenue by Type (2021-2026) & (US$ Million) Table 114. China TIGIT Therapies Revenue by Type (2027-2032) & (US$ Million) Table 115. China TIGIT Therapies Revenue by Application (2021-2026) & (US$ Million) Table 116. China TIGIT Therapies Revenue by Application (2027-2032) & (US$ Million) Table 117. Asia TIGIT Therapies Revenue by Type (2021-2026) & (US$ Million) Table 118. Asia TIGIT Therapies Revenue by Type (2027-2032) & (US$ Million) Table 119. Asia TIGIT Therapies Revenue by Application (2021-2026) & (US$ Million) Table 120. Asia TIGIT Therapies Revenue by Application (2027-2032) & (US$ Million) Table 121. Asia TIGIT Therapies Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 122. Asia TIGIT Therapies Revenue by Region (US$ Million) & (2021-2026) Table 123. Asia TIGIT Therapies Revenue by Region (US$ Million) & (2027-2032) Table 124. SAMEA TIGIT Therapies Revenue by Type (2021-2026) & (US$ Million) Table 125. SAMEA TIGIT Therapies Revenue by Type (2027-2032) & (US$ Million) Table 126. SAMEA TIGIT Therapies Revenue by Application (2021-2026) & (US$ Million) Table 127. SAMEA TIGIT Therapies Revenue by Application (2027-2032) & (US$ Million) Table 128. SAMEA TIGIT Therapies Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 129. SAMEA TIGIT Therapies Revenue by Country (2021-2026) & (US$ Million) Table 130. SAMEA TIGIT Therapies Revenue by Country (US$ Million) & (2027-2032) Table 131. Research Programs/Design for This Report Table 132. Authors List of This Report Table 133. Secondary Sources Table 134. Primary Sources List of Figures Figure 1. TIGIT Therapies Image Figure 2. Global TIGIT Therapies Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global TIGIT Therapies Market Size Share 2021 VS 2025 VS 2032 Figure 4. Monotherapy Image Figure 5. Combination Therapy Image Figure 6. Global TIGIT Therapies Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global TIGIT Therapies Market Size Share 2021 VS 2025 VS 2032 Figure 8. Cell Carcinoma Image Figure 9. Solid Tumor Image Figure 10. Global TIGIT Therapies Market Size (US$ Million) & (2021-2032) Figure 11. Global TIGIT Therapies Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global TIGIT Therapies Market Share by Region: 2021 VS 2025 VS 2032 Figure 13. Global TIGIT Therapies Players Revenue Share Top 10 and Top 5 in 2025 Figure 14. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 15. Global TIGIT Therapies Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global TIGIT Therapies Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global TIGIT Therapies Revenue Market Share by Type (2021-2032) Figure 18. Global TIGIT Therapies Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global TIGIT Therapies Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 20. Global TIGIT Therapies Revenue Market Share by Application (2021-2032) Figure 21. North America TIGIT Therapies Revenue YoY Growth (2021-2032) & (US$ Million) Figure 22. North America TIGIT Therapies Revenue Share by Type (2021-2032) Figure 23. North America TIGIT Therapies Revenue Share by Application (2021-2032) Figure 24. North America TIGIT Therapies Revenue Share by Country (2021-2032) Figure 25. United States TIGIT Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 26. Canada TIGIT Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Mexico TIGIT Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Europe TIGIT Therapies Revenue YoY Growth (2021-2032) & (US$ Million) Figure 29. Europe TIGIT Therapies Revenue Share by Type (2021-2032) Figure 30. Europe TIGIT Therapies Revenue Share by Application (2021-2032) Figure 31. Europe TIGIT Therapies Revenue Share by Country (2021-2032) Figure 32. Germany TIGIT Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. France TIGIT Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. U.K. TIGIT Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Italy TIGIT Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Spain TIGIT Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Russia TIGIT Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Netherlands TIGIT Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Nordic Countries TIGIT Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. China TIGIT Therapies Revenue YoY Growth (2021-2032) & (US$ Million) Figure 41. China TIGIT Therapies Revenue Share by Type (2021-2032) Figure 42. China TIGIT Therapies Revenue Share by Application (2021-2032) Figure 43. Asia TIGIT Therapies Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. Asia TIGIT Therapies Revenue Share by Type (2021-2032) Figure 45. Asia TIGIT Therapies Revenue Share by Application (2021-2032) Figure 46. Asia TIGIT Therapies Revenue Share by Region (2021-2032) Figure 47. Japan TIGIT Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 48. South Korea TIGIT Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. India TIGIT Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. Australia TIGIT Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Taiwan TIGIT Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Southeast Asia TIGIT Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. SAMEA TIGIT Therapies Revenue YoY Growth (2021-2032) & (US$ Million) Figure 54. SAMEA TIGIT Therapies Revenue Share by Type (2021-2032) Figure 55. SAMEA TIGIT Therapies Revenue Share by Application (2021-2032) Figure 56. SAMEA TIGIT Therapies Revenue Share by Country (2021-2032) Figure 57. Brazil TIGIT Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Argentina TIGIT Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Chile TIGIT Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Colombia TIGIT Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Peru TIGIT Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Saudi Arabia TIGIT Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Israel TIGIT Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. UAE TIGIT Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Turkey TIGIT Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Iran TIGIT Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Egypt TIGIT Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Years Considered Figure 69. Research Process Figure 70. Key Executives Interviewed

Scope & coverage.

Types
  • Monotherapy
  • Combination Therapy
Applications
  • Cell Carcinoma
  • Solid Tumor
Companies covered
  • Arcus
  • Astellas
  • BMS
  • Compugen
  • Mereo BioPharma
  • Seattle Genetics
  • AstraZeneca
  • BeiGene
  • Hengrui Medicine
  • Junshi Biosciences
  • Roche
  • Merck
  • Innovent Biologics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 TIGIT Therapies Market by Type
  3. 1.2.1 Global TIGIT Therapies Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Monotherapy
  5. 1.2.3 Combination Therapy
  6. 1.3 TIGIT Therapies Market by Application
  7. 1.3.1 Global TIGIT Therapies Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Cell Carcinoma
  9. 1.3.3 Solid Tumor
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 TIGIT Therapies Market Dynamics
  1. 2.1 TIGIT Therapies Industry Trends
  2. 2.2 TIGIT Therapies Industry Drivers
  3. 2.3 TIGIT Therapies Industry Opportunities and Challenges
  4. 2.4 TIGIT Therapies Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global TIGIT Therapies Market Perspective (2021-2032)
  2. 3.2 Global TIGIT Therapies Growth Trends by Region
  3. 3.2.1 Global TIGIT Therapies Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global TIGIT Therapies Market Size by Region (2021-2026)
  5. 3.2.3 Global TIGIT Therapies Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global TIGIT Therapies Revenue by Players
  2. 4.1.1 Global TIGIT Therapies Revenue by Players (2021-2026)
  3. 4.1.2 Global TIGIT Therapies Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global TIGIT Therapies Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global TIGIT Therapies Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global TIGIT Therapies Key Players Headquarters & Area Served
  7. 4.4 Global TIGIT Therapies Players, Product Type & Application
  8. 4.5 Global TIGIT Therapies Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global TIGIT Therapies Market CR5 and HHI
  11. 4.6.3 2025 TIGIT Therapies Tier 1, Tier 2, and Tier 3
5 TIGIT Therapies Market Size by Type
  1. 5.1 Global TIGIT Therapies Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global TIGIT Therapies Revenue by Type (2021-2032)
  3. 5.3 Global TIGIT Therapies Revenue Market Share by Type (2021-2032)
6 TIGIT Therapies Market Size by Application
  1. 6.1 Global TIGIT Therapies Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global TIGIT Therapies Revenue by Application (2021-2032)
  3. 6.3 Global TIGIT Therapies Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Arcus
  2. 7.1.1 Arcus Company Information
  3. 7.1.2 Arcus Business Overview
  4. 7.1.3 Arcus TIGIT Therapies Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Arcus TIGIT Therapies Product Portfolio
  6. 7.1.5 Arcus Recent Developments
  7. 7.2 Astellas
  8. 7.2.1 Astellas Company Information
  9. 7.2.2 Astellas Business Overview
  10. 7.2.3 Astellas TIGIT Therapies Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Astellas TIGIT Therapies Product Portfolio
  12. 7.2.5 Astellas Recent Developments
  13. 7.3 BMS
  14. 7.3.1 BMS Company Information
  15. 7.3.2 BMS Business Overview
  16. 7.3.3 BMS TIGIT Therapies Revenue and Gross Margin (2021-2026)
  17. 7.3.4 BMS TIGIT Therapies Product Portfolio
  18. 7.3.5 BMS Recent Developments
  19. 7.4 Compugen
  20. 7.4.1 Compugen Company Information
  21. 7.4.2 Compugen Business Overview
  22. 7.4.3 Compugen TIGIT Therapies Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Compugen TIGIT Therapies Product Portfolio
  24. 7.4.5 Compugen Recent Developments
  25. 7.5 Mereo BioPharma
  26. 7.5.1 Mereo BioPharma Company Information
  27. 7.5.2 Mereo BioPharma Business Overview
  28. 7.5.3 Mereo BioPharma TIGIT Therapies Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Mereo BioPharma TIGIT Therapies Product Portfolio
  30. 7.5.5 Mereo BioPharma Recent Developments
  31. 7.6 Seattle Genetics
  32. 7.6.1 Seattle Genetics Company Information
  33. 7.6.2 Seattle Genetics Business Overview
  34. 7.6.3 Seattle Genetics TIGIT Therapies Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Seattle Genetics TIGIT Therapies Product Portfolio
  36. 7.6.5 Seattle Genetics Recent Developments
  37. 7.7 AstraZeneca
  38. 7.7.1 AstraZeneca Company Information
  39. 7.7.2 AstraZeneca Business Overview
  40. 7.7.3 AstraZeneca TIGIT Therapies Revenue and Gross Margin (2021-2026)
  41. 7.7.4 AstraZeneca TIGIT Therapies Product Portfolio
  42. 7.7.5 AstraZeneca Recent Developments
  43. 7.8 BeiGene
  44. 7.8.1 BeiGene Company Information
  45. 7.8.2 BeiGene Business Overview
  46. 7.8.3 BeiGene TIGIT Therapies Revenue and Gross Margin (2021-2026)
  47. 7.8.4 BeiGene TIGIT Therapies Product Portfolio
  48. 7.8.5 BeiGene Recent Developments
  49. 7.9 Hengrui Medicine
  50. 7.9.1 Hengrui Medicine Company Information
  51. 7.9.2 Hengrui Medicine Business Overview
  52. 7.9.3 Hengrui Medicine TIGIT Therapies Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Hengrui Medicine TIGIT Therapies Product Portfolio
  54. 7.9.5 Hengrui Medicine Recent Developments
  55. 7.10 Junshi Biosciences
  56. 7.10.1 Junshi Biosciences Company Information
  57. 7.10.2 Junshi Biosciences Business Overview
  58. 7.10.3 Junshi Biosciences TIGIT Therapies Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Junshi Biosciences TIGIT Therapies Product Portfolio
  60. 7.10.5 Junshi Biosciences Recent Developments
  61. 7.11 Roche
  62. 7.11.1 Roche Company Information
  63. 7.11.2 Roche Business Overview
  64. 7.11.3 Roche TIGIT Therapies Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Roche TIGIT Therapies Product Portfolio
  66. 7.11.5 Roche Recent Developments
  67. 7.12 Merck
  68. 7.12.1 Merck Company Information
  69. 7.12.2 Merck Business Overview
  70. 7.12.3 Merck TIGIT Therapies Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Merck TIGIT Therapies Product Portfolio
  72. 7.12.5 Merck Recent Developments
  73. 7.13 Innovent Biologics
  74. 7.13.1 Innovent Biologics Company Information
  75. 7.13.2 Innovent Biologics Business Overview
  76. 7.13.3 Innovent Biologics TIGIT Therapies Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Innovent Biologics TIGIT Therapies Product Portfolio
  78. 7.13.5 Innovent Biologics Recent Developments
8 North America
  1. 8.1 North America TIGIT Therapies Revenue (2021-2032)
  2. 8.2 North America TIGIT Therapies Revenue by Type (2021-2032)
  3. 8.2.1 North America TIGIT Therapies Revenue by Type (2021-2026)
  4. 8.2.2 North America TIGIT Therapies Revenue by Type (2027-2032)
  5. 8.3 North America TIGIT Therapies Revenue Share by Type (2021-2032)
  6. 8.4 North America TIGIT Therapies Revenue by Application (2021-2032)
  7. 8.4.1 North America TIGIT Therapies Revenue by Application (2021-2026)
  8. 8.4.2 North America TIGIT Therapies Revenue by Application (2027-2032)
  9. 8.5 North America TIGIT Therapies Revenue Share by Application (2021-2032)
  10. 8.6 North America TIGIT Therapies Revenue by Country
  11. 8.6.1 North America TIGIT Therapies Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America TIGIT Therapies Revenue by Country (2021-2026)
  13. 8.6.3 North America TIGIT Therapies Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe TIGIT Therapies Revenue (2021-2032)
  2. 9.2 Europe TIGIT Therapies Revenue by Type (2021-2032)
  3. 9.2.1 Europe TIGIT Therapies Revenue by Type (2021-2026)
  4. 9.2.2 Europe TIGIT Therapies Revenue by Type (2027-2032)
  5. 9.3 Europe TIGIT Therapies Revenue Share by Type (2021-2032)
  6. 9.4 Europe TIGIT Therapies Revenue by Application (2021-2032)
  7. 9.4.1 Europe TIGIT Therapies Revenue by Application (2021-2026)
  8. 9.4.2 Europe TIGIT Therapies Revenue by Application (2027-2032)
  9. 9.5 Europe TIGIT Therapies Revenue Share by Application (2021-2032)
  10. 9.6 Europe TIGIT Therapies Revenue by Country
  11. 9.6.1 Europe TIGIT Therapies Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe TIGIT Therapies Revenue by Country (2021-2026)
  13. 9.6.3 Europe TIGIT Therapies Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China TIGIT Therapies Revenue (2021-2032)
  2. 10.2 China TIGIT Therapies Revenue by Type (2021-2032)
  3. 10.2.1 China TIGIT Therapies Revenue by Type (2021-2026)
  4. 10.2.2 China TIGIT Therapies Revenue by Type (2027-2032)
  5. 10.3 China TIGIT Therapies Revenue Share by Type (2021-2032)
  6. 10.4 China TIGIT Therapies Revenue by Application (2021-2032)
  7. 10.4.1 China TIGIT Therapies Revenue by Application (2021-2026)
  8. 10.4.2 China TIGIT Therapies Revenue by Application (2027-2032)
  9. 10.5 China TIGIT Therapies Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia TIGIT Therapies Revenue (2021-2032)
  2. 11.2 Asia TIGIT Therapies Revenue by Type (2021-2032)
  3. 11.2.1 Asia TIGIT Therapies Revenue by Type (2021-2026)
  4. 11.2.2 Asia TIGIT Therapies Revenue by Type (2027-2032)
  5. 11.3 Asia TIGIT Therapies Revenue Share by Type (2021-2032)
  6. 11.4 Asia TIGIT Therapies Revenue by Application (2021-2032)
  7. 11.4.1 Asia TIGIT Therapies Revenue by Application (2021-2026)
  8. 11.4.2 Asia TIGIT Therapies Revenue by Application (2027-2032)
  9. 11.5 Asia TIGIT Therapies Revenue Share by Application (2021-2032)
  10. 11.6 Asia TIGIT Therapies Revenue by Country
  11. 11.6.1 Asia TIGIT Therapies Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia TIGIT Therapies Revenue by Country (2021-2026)
  13. 11.6.3 Asia TIGIT Therapies Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA TIGIT Therapies Revenue (2021-2032)
  2. 12.2 SAMEA TIGIT Therapies Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA TIGIT Therapies Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA TIGIT Therapies Revenue by Type (2027-2032)
  5. 12.3 SAMEA TIGIT Therapies Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA TIGIT Therapies Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA TIGIT Therapies Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA TIGIT Therapies Revenue by Application (2027-2032)
  9. 12.5 SAMEA TIGIT Therapies Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA TIGIT Therapies Revenue by Country
  11. 12.6.1 SAMEA TIGIT Therapies Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA TIGIT Therapies Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA TIGIT Therapies Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst